Alpha Teknova, Inc.

Company Overview

Business Model: Alpha Teknova, Inc. is a leading producer of critical reagents essential for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company leverages proprietary, highly adaptable, and configurable manufacturing processes to deliver high-quality, custom, made-to-order products with short turnaround times and at scale, supporting customers across all stages of product development, including commercialization.

Market Position: Alpha Teknova, Inc. serves over 3,000 customers, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. The Company is positioned in high-growth areas such as cell and gene therapy research, development, and production, mRNA, vaccines, liquid biopsy, and genomics. Key competitive strengths include expertise in complex, custom chemical formulation manufacturing, ISO 13485:2016 certification for quality and regulatory compliance, and industry-leading delivery times for custom products (approximately 79% of custom RUO products shipped within three weeks in 2025). The Teknova brand is well established in the U.S. life sciences industry.

Recent Strategic Developments:

• Credit Facility Refinancing: On March 3, 2025, Alpha Teknova, Inc. entered into a Second Amended and Restated Credit Agreement with MidCap Financial Trust, providing a $28.245 million credit facility, including a $23.245 million senior secured term loan and a $5.0 million working capital facility. This agreement includes minimum net revenue and cash requirements, with the Company in compliance as of December 31, 2025.
• Workforce Reduction: In early 2024, the Company implemented a reduction in workforce of approximately 35 positions to reduce operating expenses, incurring $1.3 million in related costs.
• Operational Investments: Continued investment in automation, facilities, and operating infrastructure to increase manufacturing capacity, improve operating efficiency, and reduce turnaround times for custom research and GMP-grade products.

Geographic Footprint: In 2025, the United States represented 94.4% of total revenue, with international sales contributing 5.6%. International revenue was primarily derived from the United Kingdom, Canada, and Singapore. The Company plans selective geographic expansion into markets outside the U.S., particularly in Europe, through new distribution partners, localized manufacturing capabilities, and potential acquisitions.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 33.2% (2025) vs. 19.2% (2024). Excluding $2.8 million in non-recurring inventory charges in 2024, the 2024 gross margin would have been 26.5%. The 2025 improvement was driven by higher revenue and manufacturing efficiency gains.
• Operating Margin: (41.9)% (2025) vs. (69.3)% (2024)
• Net Margin: (42.6)% (2025) vs. (70.9)% (2024)

Investment in Growth:

• R&D Expenditure: $2.2 million (5.4% of revenue) in 2025, a decrease from $2.8 million in 2024, primarily due to lower salaries and wages from the early 2024 workforce reduction.
• Capital Expenditures: $1.1 million in 2025 for purchases of property, plant, and equipment.
• Strategic Investments: The Second Amended and Restated Credit Agreement includes an additional $10.0 million tranche available for acquisitions, subject to lender consent.

Business Segment Analysis

Lab Essentials

Financial Performance:

• Revenue: $31.0 million (+7.5% YoY) in 2025.
• Operating Margin: Not explicitly disclosed for this segment.
• Key Growth Drivers: An increased number of customers, partially offset by lower average revenue per customer.

Product Portfolio:

• Core products include commonly used catalog solutions and customer-specified formulations for biological research and drug discovery.
• Products are used in small, bench-scale experiments during discovery and scale up to custom products as processes optimize.
• Major product lines include pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
• New product launches or major updates: Not explicitly detailed.

Market Dynamics:

• Products are often referred to as "Research Use Only" (RUO).
• Key customer types: Genomics, spatial biology, liquid biopsy, and bioproduction.

Sub-segment Breakdown:

• Catalog Products: Approximately 75% of Lab Essentials revenue in 2025.
• Custom Products: Approximately 25% of Lab Essentials revenue in 2025.

Clinical Solutions

Financial Performance:

• Revenue: $7.7 million (+7.8% YoY) in 2025.
• Operating Margin: Not explicitly disclosed for this segment.
• Key Growth Drivers: An increased number of customers, partially offset by lower average revenue per customer.

Product Portfolio:

• Custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
• Major product lines include liquid microbial culture media and supplements for cellular expansion and molecular biology reagents for sample manipulation, resuspension, and purification.
• New product launches or major updates: Not explicitly detailed.

Market Dynamics:

• Products are often referred to as "GMP" or "GMP-grade" and are manufactured under ISO 13485:2016 certification.
• The Company has achieved substantial growth in the number of customers seeking these products annually.

Sub-segment Breakdown:

• Custom Products: Approximately 90% of Clinical Solutions revenue in 2025.
• Catalog Products: Approximately 10% of Clinical Solutions revenue in 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Alpha Teknova, Inc. has not paid any dividends since its inception and does not currently intend to declare or pay any cash dividends. The Second Amended and Restated Credit Agreement prohibits cash dividends (other than stock dividends) without prior written consent from the lender.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific commitments disclosed.

Balance Sheet Position (as of December 31, 2025, in thousands):

• Cash and Equivalents: $5,912
• Total Debt: $13,245 (excluding unamortized debt discount and debt issuance costs)
• Net Cash Position: $8,093 (Cash and Equivalents + Short-term investments - Total Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile (in thousands):
  • 2026: $0
  • 2027: $0
  • 2028: $5,519
  • 2029: $6,623
  • 2030: $1,103
  • Total: $13,245 The maturity date of the Second Amended and Restated Credit Agreement is March 1, 2030, with principal repayments beginning on April 1, 2028. Interest on the Term Loan is based on Term SOFR plus an applicable margin of 6.45%, subject to a Term SOFR floor of 3.75%.

Cash Flow Generation (in thousands):

• Operating Cash Flow: $(8,646) in 2025, compared to $(12,391) in 2024.
• Free Cash Flow: $(9,794) in 2025, compared to $(13,516) in 2024 (calculated as Operating Cash Flow minus Capital Expenditures).
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Alpha Teknova, Inc.'s operational philosophy is centered on proprietary, highly adaptable, and configurable manufacturing processes. These processes are designed to develop and manufacture customer-specified formulations rapidly, enabling the production of custom, made-to-order products with short turnaround times and at scale. The Company can provide custom solutions at low minimum volumes and scale production up to 100-fold within the same environment.

Supply Chain Architecture: Key Suppliers & Partners:

• Distributor Supplier A: Accounted for 31% of total inventory purchases in 2025 (38% in 2024). This distributor represents a diversified supply chain.
• Direct Supplier A: Accounted for 25% of total inventory purchases in 2025.
• Direct Supplier B: Accounted for 11% of total inventory purchases in 2024 (less than 10% in 2025). The Company relies on a limited number of suppliers for certain raw materials and operates on a purchase order basis without long-term supply arrangements.

Facility Network:

• Manufacturing: All products are manufactured at the Company's Hollister, California headquarters, which includes purpose-built facilities for product formulation, dispensing, packaging, and quality control.
• Research & Development: R&D activities are conducted at the Hollister campus.
• Distribution: Finished goods inventory, shipping, and raw materials storage are located at the Hollister campus. The Company ships products directly from this warehouse. The Hollister campus comprises approximately 190,000 square feet across five separate locations, including 12,500 square feet of clean room space.

Operational Metrics:

• Custom RUO delivery: Approximately 79% of custom Research Use Only (RUO) products were shipped fewer than three weeks from order placement in 2025.
• Catalog RUO delivery: Approximately 89% of catalog RUO products were shipped a week or less from order placement in 2025.
• Manufacturing efficiency gains contributed to the increase in gross profit percentage in 2025.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Alpha Teknova, Inc. primarily generates sales through its direct salesforce, engaging in direct customer relationships.
• Channel Partners: A portion of sales are generated through distributors. The Company plans to establish new relationships with distribution partners in Europe as part of its geographic expansion strategy.
• Digital Platforms: The Company maintains a website (www.teknova.com) for market access.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The Company serves leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations (CDMOs), in vitro diagnostics franchises, and academic and government research institutions.
• Customer Concentration: One distributor customer accounted for 21% of total revenue in 2025 and 18% in 2024. This distributor customer represents a highly diversified customer base.
• Customer Loyalty: Customer relationships typically span many years, driven by the integration and validation of Alpha Teknova, Inc.'s products as critical components within their own product lifecycles.
• Customer Retention: In 2025, the annual customer retention rate was approximately 95% for customers purchasing more than $10,000 annually, representing approximately 15% of the customer base and 85% of annual revenue.

Geographic Revenue Distribution:

• United States: 94.4% of total revenue in 2025 ($38.2 million).
• International: 5.6% of total revenue in 2025 ($2.3 million). Key international markets include the United Kingdom, Canada, and Singapore.
• Growth Markets: The Company identifies Europe as a strong long-term growth potential market, planning to expand its customer base through distribution partners, localized manufacturing, and potential acquisitions.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The market for biologics components and services in biopharmaceutical development, life science research, and diagnostics is intensely competitive, rapidly evolving, and subject to rapid technological change and new product introductions. Key industry factors driving future growth include the need for custom reagents for emerging therapeutic modalities (cell and gene therapies, mRNA, next-generation antibodies), demand for adaptable RUO and GMP-grade custom products with short turnaround times, the importance of GMP-grade products in regulated processes, and the increasing demand for single-use bioreactors. Industry Growth Rates:

• Global molecular diagnostics market: Estimated $31.9 billion in 2025, projected to reach $81.6 billion by 2032.
• Global genomics market: Expected to grow from an estimated $21.8 billion in 2025 to $72.5 billion by 2033.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Large, Established Companies: Thermo Fisher, Millipore (Merck KGaA), Cytiva (Danaher), Hardy Diagnostics. These competitors often have greater financial, personnel, R&D, manufacturing, and marketing resources.
• Smaller, Niche Competitors: GeminiBio, Boston BioProducts, Biologos. Alpha Teknova, Inc. believes these companies often lack the critical infrastructure and rigorous quality systems in which it has invested.
• In-house Production: A portion of target customers have established in-house production capabilities.

Emerging Competitive Threats: Increased competition from additional companies entering the market, the availability of more advanced technologies, and new approaches by competitors that could make Alpha Teknova, Inc.'s products obsolete.

Competitive Response Strategy: Alpha Teknova, Inc. aims to maintain its competitive advantage through continuous investment in customer service, operating infrastructure, quality systems, and manufacturing processes. The Company also plans selective geographic expansion and strategic partnership development to broaden its market reach and product offerings.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company's operating results may fluctuate significantly due to changes in capital market investment or governmental/academic funding for life sciences R&D, customer demand (especially from largest customers), and customer order changes (acceleration, cancellation, reduction, or delay). Market conditions, such as the contraction in funding for small and emerging biotechnology companies experienced from mid-2022 through 2023 and into 2024, can substantially impact demand. Technology Disruption: Competitors may develop new approaches that could render Alpha Teknova, Inc.'s products and technology obsolete. Customer Concentration: Revenue from top customers fluctuates, and relationships are primarily on a purchase order basis, subject to termination. Failure to maintain or increase penetration with existing customers or establish new relationships could adversely affect future operating results. Healthcare Industry Changes: Ongoing healthcare reform, adverse changes in government or private funding, and new regulations (e.g., privacy, pricing, reimbursement) could reduce demand for products or increase expenses. Cell and Gene Therapy Market Risks: Unforeseen adverse events, negative clinical outcomes, or increased regulatory scrutiny of these relatively new treatments could damage public perception and harm customer business, negatively impacting Alpha Teknova, Inc.'s revenue.

Operational & Execution Risks

Supply Chain Vulnerabilities: Dependence on a stable and adequate supply of quality raw materials, with a limited number of suppliers (two suppliers accounted for 56% of total inventory purchases in 2025). Price increases, supply chain disruptions, or lack of long-term supply arrangements could adversely impact operations. Geographic Concentration: Manufacturing and storage operations are located in Hollister, California, near major earthquake faults, exposing the Company to earthquake and fire risks. Reliance on local water supply also presents a risk, particularly during extended drought conditions. Capacity Constraints: Efforts to scale manufacturing capabilities could be disruptive, and delays in expansion or failure to meet projected capacity could adversely affect results. Product Quality: Despite rigorous quality control, nonconformances, defects, or errors could occur, leading to lost revenue, delayed market acceptance, increased costs, and damage to reputation. Failure to maintain ISO 13485:2016 certification could also harm operations. Delivery: Disruptions in manufacturing or shipping, including reliance on third-party package delivery services, could delay revenue recognition, increase costs, and damage customer relationships. Personnel: Inability to hire and retain skilled management, technical, and other staff, or the loss of key personnel, could hinder product development and business prospects. Information Technology: Reliance on internal and third-party IT systems makes the Company vulnerable to cyberattacks, security breaches, and system failures, which could disrupt business operations, damage reputation, and incur significant costs.

Financial & Regulatory Risks

Market & Financial Risks: Alpha Teknova, Inc. has incurred operating losses and may continue to do so. Future capital needs are uncertain, and additional financing may be required, potentially leading to dilution or unfavorable terms. Existing indebtedness under the Second Amended and Restated Credit Agreement could divert funds, impair liquidity, and impose operating restrictions. Regulatory & Compliance Risks: While products are currently exempt from FDA medical device and drug regulations, future changes in interpretation or intended use could subject them to such regulations, increasing costs and delaying commercialization. Compliance with "Research Use Only" labeling guidance is critical. The Company is also subject to various federal, state, local, and international laws and regulations (e.g., environmental, health, safety, anti-corruption). Legal Proceedings: The Company may become subject to product liability claims, intellectual property litigation, or other legal proceedings, which could be costly, time-consuming, and damage its reputation. Tax Strategy: The Company's ability to utilize net operating loss (NOL) carryforwards ($90.3 million federal, $81.2 million state as of December 31, 2025) may be limited by ownership changes (Sections 382 and 383) or other tax law changes. A valuation allowance of $27.052 million was recorded against deferred tax assets as of December 31, 2025.

Geopolitical & External Risks

Geopolitical Exposure: Natural disasters (e.g., earthquakes, fire, drought in California), geopolitical unrest, war, terrorism, public health issues, or other catastrophic events could disrupt supply, production, delivery, or demand for products. Trade Relations: Changes in tariff and international trade policy, which began in 2025, could create economic uncertainty and negatively impact the business.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Alpha Teknova, Inc.'s R&D efforts are focused on process engineering and manufacturing science functions, which underpin its ability to provide complex, custom chemical formulations. Innovation Pipeline: The Company aims to develop additional relevant products and applications for its target markets, particularly in high-growth areas like cell and gene therapy, mRNA, and molecular diagnostics.

Intellectual Property Portfolio:

• Patent Strategy: Alpha Teknova, Inc. does not currently own any issued patents covering its proprietary products or manufacturing processes but may pursue patent applications or acquire/license intellectual property rights in the future.
• Licensing Programs: Not explicitly detailed.
• IP Litigation: No material IP litigation is currently disclosed, but the Company acknowledges the risk of third-party claims of infringement or misappropriation, which could be costly.

Technology Partnerships: The Company may explore partnerships, collaborations, or acquisitions to add complementary capabilities and expand product offerings, both domestically and internationally.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's success is highly dependent on the continued service of its management, technical, and other staff. Equity incentive plans are in place to attract, retain, and motivate personnel.

Board Composition: The board of directors includes Stephen Gunstream, Paul Grossman (Chairman), Irene Davis, Martha J. Demski, Alexander Herzick, J. Matthew Mackowski, Brett Robertson, and Alexander Vos. Alpha Teknova, Inc. is a "controlled company" under Nasdaq rules, with Telegraph Hill Partners Management Company LLC (THP) controlling approximately 70.4% of the voting power. As a result, the Company relies on exemptions from certain corporate governance requirements, such as having a majority independent board or fully independent compensation and nominating committees.

Human Capital Strategy

Workforce Composition:

• Total Employees: 158 full-time employees as of December 31, 2025.
• Geographic Distribution: All employees are located in Hollister, California.
• Skill Mix: The workforce is distributed across operations (88 employees), administrative functions (45 employees), sales and marketing (15 employees), and engineering and research and development (10 employees).

Talent Management: Acquisition & Retention: The Company's human capital objectives include identifying, recruiting, retaining, incentivizing, and motivating employees. The Company faces significant competition for skilled personnel. Equity incentive plans (2016 Stock Plan, 2020 Equity Incentive Plan, 2021 Equity Incentive Plan, and 2021 Employee Stock Purchase Plan) are utilized to attract and retain talent through stock-based compensation. Employee Value Proposition: Not explicitly detailed beyond equity incentive plans.

Diversity & Development: Not explicitly detailed.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: The Company acknowledges the increasing effects of climate change as a risk factor that could disrupt its operations. Supply Chain Sustainability: Not explicitly detailed.

Social Impact Initiatives: Not explicitly detailed.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed.
• Economic Sensitivity: Customer spending on research, development, production, and marketing is significantly influenced by capital market investment, governmental and academic funding, and general economic conditions. The Company experienced a sharp contraction in funding for small and emerging biotechnology companies from mid-2022, with negative market dynamics persisting through 2023 and to a lesser extent in 2024.
• Industry Cycles: The Company's revenue and profitability are substantially impacted by these cyclical changes in customer spending and funding availability.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Alpha Teknova, Inc. markets its products as ancillary reagents and materials for research or further manufacturing, believing them to be exempt from the U.S. Federal Food, Drug and Cosmetic Act (FDCA) and FDA's current Good Manufacturing Practice (GMP) regulations. The Company voluntarily maintains a quality system compliant with ISO 13485:2016 standards and is certified to manufacture products in accordance with these standards. International Compliance: The Company's biopharmaceutical and life sciences customers are subject to extensive regulation by the FDA and corresponding regulatory authorities in other countries, which imposes rigorous quality requirements on Alpha Teknova, Inc. as a supplier.

Trade & Export Controls: Changes to tariff and related international trade policy, which began in 2025, have created uncertainty for the broader economy and the Company's business.

Legal Proceedings: As of the filing date, Alpha Teknova, Inc. is not a party to any material legal proceedings. In April 2025, the Company paid a $0.4 million settlement for a former employee's claim alleging various causes of action under California labor laws, which was accrued as of December 31, 2024.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: (0.3)% in 2025 and 0.3% in 2024.
• Geographic Tax Planning: Alpha Teknova, Inc. is subject to income taxes in the U.S. federal jurisdiction and various states. There are no foreign income taxes.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025, did not have a significant impact on the Company's financial statements and is not expected to materially impact future periods.
• NOL Carryforwards: As of December 31, 2025, the Company had $90.3 million in U.S. federal and $81.2 million in state net operating loss (NOL) carryforwards. Federal NOLs incurred after 2019 carry forward indefinitely but are subject to an 80% taxable income limitation after December 31, 2022. State NOLs begin to expire in 2036.
• Tax Credit Carryforwards: As of December 31, 2025, the Company had $0.6 million in federal research and development tax credit carryforwards (expiring in 2035) and $0.2 million in state research and development tax credit carryforwards (carrying forward indefinitely).
• Valuation Allowance: A net increase in valuation allowances of $4.5 million was recorded in 2025, primarily on NOLs not expected to be realizable. The total valuation allowance was $27.052 million as of December 31, 2025.
• Tax Examinations: The Company is currently under examination by the Internal Revenue Service for the 2023 tax year.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Alpha Teknova, Inc. maintains product liability insurance, subject to deductibles, limits, and exclusions. The Company also has a Directors and Officers (D&O) liability insurance policy, with premiums financed through an agreement with First Insurance Funding.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance policies.